Quick answer: In November 2025, the FDA announced it would remove most of the “black box” warning from menopause hormone therapy, and updated prescribing information is now available for these products (U.S. Food and Drug Administration [FDA], 2026). The change reflects newer research, but hormone therapy is not risk-free. The right choice still depends on your age, how long it has been since menopause, your symptoms, and your health history (The Menopause Society, 2025).
What was the black box warning, and why was it added?
To understand why this matters, it helps to know what was removed. A black box warning is the FDA’s strongest safety alert, placed at the top of a drug’s label to flag its most serious risks. It is the strongest action the FDA can take short of removing a drug from the market.
The warning began after the Women’s Health Initiative (WHI) studies were stopped early in 2002 and 2004. Researchers reported higher risks of breast cancer, stroke, and probable dementia. In response, the FDA added a boxed warning to menopause hormone therapy starting in 2003 (FDA, 2026). For more than 20 years, the warning discouraged many women from considering treatment (Harvard Health Publishing, 2025).
What Changed on the Menopause Hormone Therapy Label?
The FDA requested these key updates to menopause hormone therapy labels (FDA, 2026):
- All products, including vaginal estrogen: The boxed warning no longer includes cardiovascular disease, breast cancer, or probable dementia.
- Endometrial cancer: This language was removed from the boxed warning except on systemic estrogen-alone products, which still carry it.
- Dosing language: The recommendation to use the “lowest effective dose for the shortest amount of time” was removed.
- Timing guidance for systemic products: Labels now say hormone therapy can be considered for moderate to severe hot flashes in women under 60 or within 10 years of menopause.
- Remaining warnings: Information about cardiovascular disease and breast cancer stays in the body of the label for systemic products.
In other words, these risks were moved out of the boxed warning, not erased from the label entirely.
Why did the FDA make this change?
The FDA’s review found that the original warning didn’t reflect the women who typically use hormone therapy(FDA, 2026):
- The study population was older. WHI participants averaged 63 years old, but most women develop bothersome hot flashes between ages 45 and 55. The average age of menopause in the U.S. is 51.
- Many women who could benefit weren’t being treated. About 41 million U.S. women were aged 45 to 64 in 2020, and roughly 34% of women aged 45 to 65 experienced moderate to severe hot flashes. Yet only about 2 million women aged 46 to 65 received a prescription for systemic hormone therapy in 2020.
Does This Mean HRT Is Safe for Everyone?
No. The Menopause Society supported the FDA’s decision but noted that systemic estrogen still carries potential risks. These risks are low for younger, healthy women who start near menopause and greater for older women or those further from menopause (The Menopause Society, 2025). The full label also still includes warnings about cardiovascular disease and breast cancer, so women with a history of blood clots, stroke, or breast cancer need especially careful evaluation (FDA, 2026).
It also helps to be clear about what hormone therapy is meant to do. Its main role is relieving menopause symptoms such as hot flashes, night sweats, and vaginal dryness, and some products are also approved to help prevent bone loss (FDA, 2026). Hormone therapy is not indicated for preventing dementia or frailty, and care should be individualized based on age, symptom severity, personal and family risk, other health conditions, and personal preference (European Menopause and Andropause Society [EMAS], 2025).
Who May Be a Good Candidate for Menopause Hormone Therapy?
Hormone therapy may be worth discussing with your provider if:
- You have moderate to severe menopause symptoms and are under 60 or within 10 years of menopause. This is the group the updated labels specifically address (FDA, 2026).
- You’re outside that window but still have symptoms. Other women can also be candidates after an evaluation (Abels, 2025).
A few other points affect which treatment is appropriate:
- If you still have your uterus, you’ll also need progesterone with estrogen to protect against endometrial cancer (Abels, 2025).
- Some women may be less suited to systemic therapy, including those who have had breast cancer, a heart attack, a stroke, or blood clots, or who have active liver or gallbladder disease. Non-hormonal options are available for these women (Abels, 2025).
What about vaginal estrogen?
Local vaginal estrogen comes as creams, rings, and tablets, and it’s designed to treat symptoms like vaginal dryness and urinary urgency. Because only trace amounts reach the bloodstream, it’s considered a low-risk option, but it won’t relieve whole-body symptoms like hot flashes (Abels, 2025).
Under the new labeling, vaginal estrogen products no longer carry the boxed warning, and their safety information has been condensed to focus on what’s relevant to local use (FDA, 2026). To learn how local and systemic options compare, read our guide to local vs. systemic estrogen therapy.
What does this mean for bioidentical hormones?
Bioidentical hormones are identical to the hormones women’s bodies naturally produce, and the FDA has approved hormone therapies that contain them. The label update applies to FDA-approved products. Many products marketed as “bioidentical hormones” are compounded preparations, which are not FDA-approved and don’t carry FDA labeling (FDA, n.d.).
At Androgenix, your provider will explain the type of hormone therapy being recommended and why it fits your needs. Learn more about our bioidentical hormone replacement therapy (BHRT) services.
Questions to Ask Your Provider About Menopause Hormone Therapy
Before your appointment, write down your symptoms in order of how much they bother you, along with your current medications, past health events, how long it’s been since your last period, and your family health history (Abels, 2025). Then ask:
- Based on my age and time since menopause, is hormone therapy a reasonable option for me? Timing is central to the updated labels (FDA, 2026).
- Does my health history change my options? A history of breast cancer, heart attack, stroke, blood clots, or liver or gallbladder disease can affect what’s appropriate (Abels, 2025).
- Do I need progesterone along with estrogen? This is usually needed if you still have your uterus (Abels, 2025).
- Is a local or systemic option better for my symptoms? Local therapy targets vaginal and urinary symptoms, while systemic therapy treats whole-body symptoms like hot flashes (Abels, 2025).
- Which formulation do you recommend, and why? Treatment should be matched to your symptoms, risks, and preferences (EMAS, 2025).
- How will we monitor my progress? Finding the right dose and regimen can take a few visits and adjustments (Abels, 2025).
How Androgenix Can Help
If you’re experiencing hot flashes, night sweats, sleep changes, or other menopause symptoms, or you have questions about whether hormone therapy is right for you, a proper evaluation can help identify the right approach.
Androgenix provides personalized hormone health services for women, including comprehensive lab testing, a review of your health history, and individualized hormone therapy options when they’re appropriate.
Learn more about:
- HRT for Women: Benefits, Risks, and What to Expect
- Estrogen Replacement Therapy: Comparing Local vs Systemic Estrogen
- Low Estrogen Symptoms: When to Test and What Treatment Can Do
- Bioidentical Hormone Replacement Therapy (BHRT)
- Comprehensive Hormone Testing
FAQs About Menopause Hormone Therapy and the FDA Label Change
Did the FDA say HRT is completely safe now?
No. Cardiovascular and breast cancer warnings remain in the full label for systemic products, and systemic estrogen-alone products keep the boxed warning for endometrial cancer (FDA, 2026). Risks are low for younger, healthy women starting near menopause and greater for older women or those further from menopause (The Menopause Society, 2025).
Does the change apply to compounded or bioidentical hormones?
Not directly. The update applies to FDA-approved products (FDA, 2026). Many products marketed as “bioidentical hormones” are compounded and not FDA-approved, so they don’t carry an FDA label (FDA, n.d.). Your provider can explain which option fits your needs.
Is vaginal estrogen affected?
Yes. Vaginal estrogen products no longer carry the boxed warning, and their safety information has been condensed to focus on local use (FDA, 2026).
Can I start HRT if I’m over 60?
Possibly, but it requires more careful evaluation. The updated labels focus on women under 60 or within 10 years of menopause (FDA, 2026), and risks are greater when therapy starts later (The Menopause Society, 2025). Still, women outside that window can be candidates after an evaluation (Abels, 2025).
Medical Disclaimer
This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Individual results may vary.
